Generic drug maker Lotus Pharmaceuticals Co (美時化學製藥) yesterday said it has made non-material adjustments to its financial statements for 2016 and 2017 after South Korean regulators found minor accounting errors at its subsidiary there.
The subsidiary, Alvogen Korea Co Ltd, was included in an industry-wide probe by the South Korean Financial Supervisory Service (FSS), following a high-profile case in April last year against alleged accounting violations at Samsung BioLogics Co, the biotechnology arm of the South Korean tech giant.
Lotus Pharmaceuticals has since revised its earnings, resulting in a NT$15 million (US$493,729) decrease in its 2016 net income and a NT$14 million increase in 2017, the local firm said.
Following the adjustments, the company reported a net loss of NT$0.63 per share for 2016, compared with a previous net loss of NT$0.56 per share.
For 2017, the company’s earnings per share inched up from NT$0.03 to NT$0.09.
The company said that the error is rooted in the difference of interpretation on South Korea’s international financial reporting standards principles regarding development costs of the company’s Incremental Modified Drug (IMD) pipeline.
IMD, or more widely known as 505(b)(2), is an alternative US Food and Drug Administration approval pathway designed to allow the approval of a drug that is not new, but still differs in several meaningful aspects.
While the classification of IMD as generic or new drug products remains a debated area among accounting experts, the company said it has accepted the decision of the FSS.
IMD falls between New Drug Application that is seeking approval to introduce a new drug to the market and Abbreviated New Drug Application (ANDA), which aims to gain approval for a generic version of a drug that is already on the market, according to US FDA guidelines.
The FSS in November last year fined Samsung Biologics US$7.04 million and recommended dismissing its chief executive officer for deliberately overstating the value of its affiliate ahead of the unit’s initial public offering that later raised about US$2 billion.
Lotus Pharmaceuticals has reported that sales in the past month rose 0.7 percent annually to NT$529 million, while aggregate sales in the past year rose 1.1 percent annually to NT$6.35 billion.
Higher generic drug demand from Taiwan and overseas helped offset the loss of licensing fee income, while the introduction of its new Lenalidomide chemotherapy to markets in Europe, the Middle East and Asia would help support sales growth this quarter, the industry’s slow season, the company said.
CHIP HANG-UP: Surging memorychip prices would deal a blow to smartphone sales this year, potentially hindering one of MediaTek’s biggest sources of revenue MediaTek Inc (聯發科), the world’s biggest smartphone chip designer, yesterday said its new artificial intelligence (AI) chips used in data centers are to account for 20 percent of its total revenue next year, as cloud service providers race to deploy AI infrastructure to meet voracious demand. MediaTek is believed to be developing tensor processing units for Google, which are used in AI applications. While it did not confirm such reports, MediaTek said its new application-specific IC (ASIC) business would be a new growth engine for the company. It again hiked its forecast for the addressable ASIC market to US$70 billion by 2028, compared
MediaTek Inc (聯發科), the world’s biggest smartphone chip supplier, yesterday said it plans to double investment in data center-related technologies, including advanced packaging and high-speed interconnect technologies, to broaden the new business’ customer and service portfolios. The chip designer is redirecting its resources to data centers, mainly designing application-specific integrated circuits (ASIC) with artificial intelligence (AI) capabilities for cloud service providers. The data center business is forecast to lead growth in the next three years and become the company’s second-biggest revenue source, replacing chips used in smart devices, MediaTek president Joe Chen (陳冠州) told a media event in Taipei. “Three or four years
Motorists ride past a mural along a street in Varanasi, India, yesterday.
Until US President Donald Trump’s return a year ago, when the EU talked about cutting economic dependency on foreign powers — it was understood to mean China, but now Brussels has US tech in its sights. As Trump ramps up his threats — from strong-arming Europe on trade to pushing to seize Greenland — concern has grown that the unpredictable leader could, should he so wish, plunge the bloc into digital darkness. Since Trump’s Greenland climbdown, top officials have stepped up warnings that the EU is dangerously exposed to geopolitical shocks and must work toward strategic independence — in defense, energy and
RSS